Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro
- PMID: 14654560
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro
Abstract
Purpose: A group of histone deacetylase inhibitors has been shown to be effective in suppressing the growth of a variety of transformed cell lines in vitro and in vivo. The effects of two of these agents, suberoylanilide hydroxamic acid (SAHA) and suberoyl-3-aminopyridineamide hydroxamic acid (pyroxamide), were investigated for their growth-suppressive effects on rhabdomyosarcoma (RMS) cells.
Experimental design and results: Dose-response experiments of two RMS cell lines, RD (embryonal) and RH30B (alveolar), were performed with SAHA (0.25-3.0 micro M) and pyroxamide (1.25-20.0 micro M). Both agents caused a dose-dependent decrease in viable cell number and an increase in percentage of dead cells over time. Exposure of the RMS cells to SAHA and pyroxamide resulted in an accumulation of acetylated histones with increasing doses by Western blot analysis. Additionally, there was an induction of p21/WAF1 at 15 and 24 h when the cells were cultured with SAHA (2.0 micro M) or pyroxamide (20.0 micro M), concentrations that were tested because they successfully induced inhibition of cell growth and initiated cell death in both RMS cell lines. An increase in nuclei with hypodiploid or sub-G(1) fraction was found by flow cytometry with increasing doses of both SAHA (0.25-3.0 micro M) and pyroxamide (1.25-20.0 micro M) over time. This finding is consistent with DNA fragmentation and cell death by apoptosis.
Conclusions: SAHA and pyroxamide induce growth suppression and cell death in human RMS in vitro. Accumulation of acetylated histones and induction of p21/WAF1 expression are observed in cells exposed to either agent.
Similar articles
-
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.Cancer Res. 2000 Sep 15;60(18):5165-70. Cancer Res. 2000. PMID: 11016644
-
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.Clin Cancer Res. 2007 Feb 1;13(3):1045-52. doi: 10.1158/1078-0432.CCR-06-1261. Clin Cancer Res. 2007. PMID: 17289901
-
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.Eur J Haematol. 2006 Jan;76(1):42-50. doi: 10.1111/j.1600-0609.2005.00546.x. Eur J Haematol. 2006. PMID: 16343270
-
Discovery and development of SAHA as an anticancer agent.Oncogene. 2007 Feb 26;26(9):1351-6. doi: 10.1038/sj.onc.1210204. Oncogene. 2007. PMID: 17322921 Review.
-
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.Nat Clin Pract Oncol. 2005 Mar;2(3):150-7. doi: 10.1038/ncponc0106. Nat Clin Pract Oncol. 2005. PMID: 16264908 Review.
Cited by
-
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.Pediatr Blood Cancer. 2009 Sep;53(3):505-8. doi: 10.1002/pbc.21988. Pediatr Blood Cancer. 2009. PMID: 19418547 Free PMC article.
-
Role of epigenetic modulation for the treatment of sarcoma.Curr Treat Options Oncol. 2013 Sep;14(3):454-64. doi: 10.1007/s11864-013-0239-3. Curr Treat Options Oncol. 2013. PMID: 23749746
-
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.Cancer Discov. 2017 Aug;7(8):884-899. doi: 10.1158/2159-8290.CD-16-1297. Epub 2017 Apr 26. Cancer Discov. 2017. PMID: 28446439 Free PMC article.
-
Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.Mol Cancer Ther. 2011 Feb;10(2):313-24. doi: 10.1158/1535-7163.MCT-10-0724. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216937 Free PMC article.
-
Comparison of Anticancer Effects of Carbamazepine and Valproic Acid.Iran Red Crescent Med J. 2016 Aug 4;18(10):e37230. doi: 10.5812/ircmj.37230. eCollection 2016 Oct. Iran Red Crescent Med J. 2016. PMID: 28184324 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous